1. Search Result
Search Result
Results for "


" in MCE Product Catalog:


Inhibitors & Agonists


Screening Libraries



Cat. No. Product Name Target Research Areas
  • HY-129987
    Estradiol 17-(β-D-Glucuronide) (sodium)

    Endogenous Metabolite Endocrinology Metabolic Disease
    Estradiol 17-(β-D-Glucuronide) sodium, a metabolite of estrogen, is well known to cause intrahepatic cholestasis in humans.
  • HY-B0172
    Lithocholic acid

    3α-Hydroxy-5β-cholanic acid

    Autophagy Endogenous Metabolite Apoptosis Metabolic Disease
    Lithocholic acid is a toxic secondary bile acid, causes intrahepatic cholestasis, has tumor-promoting activity.
  • HY-N0805
    Alisol B 23-acetate

    23-Acetylalismol B; 23-O-Acetylalisol B; Alisol B monoacetate

    Others Others
    Alisol B 23-acetate (23-Acetylalismol B), a natural triterpenoid, produces protective effects against EE-induced cholestasis, due to FXR-mediated gene regulation.
  • HY-136066
    Tauro-ω-muricholic acid sodium

    TωMCA sodium

    Others Metabolic Disease
    Tauro-ω-muricholic acid sodium (TωMCA sodium) is a bile acid released by the liver and an analog of tauro-α-muricholic acid. Tauro-ω-muricholic acid sodium is investigated as a potential marker in plasma for early-onset neonatal sepsis (EOS) and cholestasis studies
  • HY-16747
    Maralixibat chloride

    SHP625 chloride; LUM001 chloride; Lopixibat chloride

    Others Metabolic Disease
    Maralixibat (SHP625) chloride is an orally active ileal bile acid transporter (IBAT) inhibitor. Maralixibat chloride can be used for the treatment of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia.
  • HY-B1899A
    Taurodeoxycholic acid sodium hydrate

    Sodium taurodeoxycholate monohydrate

    Caspase Apoptosis Metabolic Disease Inflammation/Immunology
    Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate) prevents apoptosis by blocking a calcium-mediated apoptotic pathway as well as caspase-12 activation. Taurodeoxycholic acid sodium hydrate is investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis.
  • HY-139562

    FXR Metabolic Disease
    BMS-986318 is a potent nonbile acid FXR agonist with EC50s of 53 and 350 nM in the FXR Gal4 and SRC-1 recruitment assays, respectively. BMS-986318 has a suitable ADME profile, and demonstrates efficacy in the mouse bile duct ligation model of liver cholestasis and fibrosis.BMS-986318 can be used for the research of nonalcoholic steatohepatitis.